Provectus Biopharmaceuticals Inc.
7327 Oak Ridge Highway
349 articles about Provectus Biopharmaceuticals Inc.
Clinical Catch-Up: October 25-29
11/1/2021Yet another busy week for clinical trial news. Here’s a look.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON GI CANCER PROGRAM FOR INVESTIGATIONAL DRUG PV-10
Ongoing Phase 1 basket study of PV-10 for cancers of the liver expanded to include single-center cohort of metastatic uveal melanoma patients
PROVECTUS BIOPHARMACEUTICALS CLINICAL TRIALS UPDATE PROVIDED AT EUROPEAN POST-CHICAGO MELANOMA/SKIN CANCER MEETING
Provectus announced that a clinical trials update was provided at the 8th European Post-Chicago Melanoma/Skin Cancer Meeting, held in Munich, Germany from June 28-29.
Think biotechnology, you probably think cutting-edge development of drugs to treat diseases. Yet in 2007, a U.S. EPA report noted that industrial biotechnology and biobased manufacturing are more efficient, cleaner and make better use of sustainable renewable resources.
PROVECTUS BIOPHARMACEUTICALS EXPANDS GLOBAL PATENT PORTFOLIO FOR ACTIVE PHARMACEUTICAL INGREDIENT MANUFACTURE
Provectus today announced that the Indian Patent Office (IPO) has granted the Company’s patent application for the synthetic process used to produce the active pharmaceutical ingredient (API) in PV-10, which is Provectus’ lead investigational oncology drug.
Craig Dees, CEO of Provectus treated the company as "his own personal piggy bank" by submitting hundreds of falsified records to obtain $3.2M for personal expenses
Provectus Reestablishes Strategic Advisory Board
Provectus Closes Definitive Financing With PRH Group
Provectus Announces Terms Of Definitive Financing Commitment
Provectus Enters Into Definitive Financing Commitment Term Sheet
Provectus Announces Extension Of Rights Offering Due To Receipt Of Unsolicited Investment Proposals To Invest In Provectus
Provectus Provides Information On Rights Offering Deadline
Provectus Appoints Bruce Horowitz And Dominic Rodrigues As Special Advisers To The Board Of Directors
Provectus Announces Extension Of Rights Offering
Provectus Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants
Provectus Fires Peter Culpepper as Interim CEO and COO
Provectus Announces Two Poster Presentations On PV-10 For Liver Tumors
Provectus Announces Agreement With POETIC (Pediatric Oncology Experimental Therapeutics Investigators Consortium) To Study Potential Of PV-10 For Pediatric Cancer